April 1, 2012
By:G. Steven Burrill
Better news about the global economy buoys life-sciences funding.
 |
January 1, 2012
By:G. Steven Burrill
Greater emphasis on focus and efficiency for companies as market demands value in 2012.
|
October 1, 2011
By:G. Steven Burrill
Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings
|
July 1, 2011
By:G. Steven Burrill
Strong pipelines, approvals, and deals drive up market cap.
|
January 1, 2011
By:G. Steven Burrill
Business models that were used to create current value are no longer going to be effective going forward.
|
October 1, 2010
By:G. Steven Burrill
Biotech's mid-sized elites position themselves for growth.
|
July 1, 2010
By:G. Steven Burrill
After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.
|
April 1, 2010
By:G. Steven Burrill
As the capital markets in the US and globally continue to strengthen, the biotech industry can expect to see a rise in initial public offerings this year.
|
| 
